Kringle Pharma, Inc.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥392M | ¥69M | ¥80M | ¥72M |
| Gross Profit | ¥303M | ¥69M | ¥80M | ¥72M |
| Operating Income | -¥426M | -¥889M | -¥818M | -¥909M |
| Pretax Income | -¥426M | -¥889M | -¥818M | -¥909M |
| Net Income | -¥332M | -¥854M | -¥756M | -¥916M |
| EPS | -¥68.33 | -¥158.46 | -¥118.21 | -¥133.92 |
| Operating Margin | -108.76% | -1,283.41% | -1,021.87% | -1,259.37% |
| Balance Sheet | ||||
| Total Assets | ¥3,209M | ¥2,619M | ¥2,757M | ¥2,079M |
| Total Equity | ¥2,789M | ¥2,022M | ¥2,108M | ¥1,309M |
| Total Liabilities | ¥420M | ¥597M | ¥649M | ¥770M |
| Cash | ¥2,756M | ¥2,136M | ¥2,313M | ¥1,619M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 86.93% | 77.20% | 76.46% | 62.96% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥16M | -¥689M | -¥661M | -¥756M |
| Investing CF | -¥254M | -¥121M | -¥121M | -¥154M |
| Financing CF | ¥603M | ¥69M | ¥838M | ¥84M |
| Free CF | ¥16M | -¥689M | -¥661M | -¥756M |
| Efficiency | ||||
| ROE | -11.90% | -42.25% | -35.88% | -69.98% |
| ROA | -10.34% | -32.62% | -27.44% | -44.06% |
Latest IR Information
-
Financial Summary for the Third Quarter of Fiscal Year Ending September 2026 (Japan GAAP) (Consolidated)
For the third quarter of FY2026, net sales were 323 million yen, operating loss of 633 million yen, ordinary loss of 628 million yen, and quarterly net loss of 631 million yen. Compared with the same period last year, sales...
Read more -
Notice of the Third Quarter Financial Results for the Fiscal Year Ending September 2026
Announcement of the third quarter results for the fiscal year ending September 2026. Reports on trends in sales and profits, segment-by-segment performance, outlook, progress in R&D and pipeline, and capital policy and risk factors.
Read more -
Notice on Monthly Exercise Status of the 16th Series of New Share Subscription Rights Issued through Third-Party Allotment, with Exercise Price Modification Clause
Read more -
Notice of Public Disclosure of Registration Information for Phase III Additional Clinical Trial of HGF (Hepatocyte Growth Factor) in the Acute Phase of Spinal Cord Injury
Read more -
Notice Regarding the Reduction of Capital and Capital Reserve Amounts, as well as the Disposition of Surplus Funds
Read more
Latest News (5 items)
Company Information
About
Kringle Pharma, Inc. engages in research and develops therapeutic agents for the treatment of intractable diseases in Japan. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Kita, Japan.
